Journal Home
Search for

Volume 52, Issue 6, Pages 1084-1095 (December 2008)


View previous. 9 of 37 View next.

Effect of Hydrochlorothiazide on Urinary Calcium Excretion in Dent Disease: An Uncontrolled Trial

Anne Blanchard, MD, PhD123Corresponding Author Informationemail address, Rosa Vargas-Poussou, MD, PhD1245, Severine Peyrard, MSc23, Agnes Mogenet, MD67, Veronique Baudouin, MD, PhD8910, Bernard Boudailliez, MD, MSc1112, Marina Charbit, MD168, George Deschesnes, MD, PhD8910, Nadia Ezzhair, MD10, Chantal Loirat, MD, PhD8910, Marie-Alice Macher, MD, PhD8910, Patrick Niaudet, MD, PhD169, Michel Azizi, MD, PhD123

Received 26 March 2008; accepted 1 August 2008. published online 03 November 2008.

Background

Thiazide doses equivalent to 1 to 2 mg/kg/d of hydrochlorothiazide (HCTZ) have been proposed to correct hypercalciuria and prevent kidney failure in patients with Dent disease. However, they can cause adverse metabolic effects in the long term. In treating hypertension in children, lower thiazide doses have been shown to be as effective and well tolerated.

Study Design

Uncontrolled trial, with forced-titration sequential open-label study design.

Setting & Participants

7 boys with genetically confirmed Dent disease and mild phenotype (neither overt sodium wasting nor kidney failure).

Intervention

After a 1-month run-in period, patients sequentially received amiloride (5 mg/d) alone (1 month) and then for 3 periods of 2 months in association with increasing doses of HCTZ (<0.2, 0.2 to 0.4, and 0.4 to 0.8 mg/kg/d).

Outcomes

Urinary calcium excretion and extracellular volume indicators.

Measurements

At the end of each period, 2 daily 24-hour urinary collections were performed on the days preceding admission. Blood and spot urine samples also were collected.

Results

A greater HCTZ dose increased renin, aldosterone, and plasma protein concentrations. Amiloride alone had no effect on calcium excretion. The greatest HCTZ doses decreased spot urinary calcium excretion by 42% compared with baseline (median, 0.3; minimum, maximum, 0.2, 0.8 versus median, 0.8; minimum, maximum, 0.4, 1.1, respectively; P = 0.03). However, patients developed adverse reactions, including muscle cramps (n = 2), biological (n = 7) or symptomatic hypovolemia (n = 1), hypokalemia (n = 4), and hyponatremia (n = 1), which all corrected after treatment withdrawal.

Limitation

Small sample size and absence of a control group.

Conclusion

HCTZ doses greater than 0.4 mg/kg/d decreased calcium excretion, but were associated with significant adverse events. Thiazide diuretic therapy should be considered with caution in children with Dent disease.

1 Université Paris 5, Faculté de Médecine Paris Descartes, France

2 Assistance Publique-Hôpitaux de Paris, Hôpital Européen George Pompidou, France

3 Centre d'Investigations Cliniques 9201, France

4 Département de Génétique, France

5 INSERM U772, Paris, France

6 Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfant Malade, France

7 Centre d'Investigations Cliniques, France

8 Service de Néphrologie, France

9 Faculté de Médecine, Université Paris 7, France

10 Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, France

11 Université de Picardie, faculté de médecine, Assistance Publique-Hôpitaux de Paris, France

12 Centre Hospitalier Amiens Sud, Département de Néphrologie Pédiatrique, France

Corresponding Author InformationAddress correspondence to Anne Blanchard, MD, PhD, Centre d'Investigation Cliniques, Hôpital Européen Georges Pompidou, 20-40 rue Leblanc, F-75015 Paris

 Trial registration: ClinicalTrials.gov; study number: NCT00638482.

 Originally published online as doi:10.1053/j.ajkd.2008.08.021 on November 3, 2008.

PII: S0272-6386(08)01347-4

doi:10.1053/j.ajkd.2008.08.021


View previous. 9 of 37 View next.